| Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL): a randomised, double-blind… | McGuire DK | New England Journal of Medicine | 2025 | Journal article | 6 |
| Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis | Sanyal AJ | New England Journal of Medicine | 2025 | Journal article | 3 |
| Tirzepatide as compared with semaglutide for the treatment of obesity | Aronne LJ | New England Journal of Medicine | 2025 | Journal article | 11 |
| Tirzepatide for heart failure with preserved ejection fraction and obesity | Packer M | New England Journal of Medicine | 2025 | Journal article | 1 |
| A phase 2 randomized trial of survodutide in MASH and fibrosis | Sanyal AJ | New England Journal of Medicine | 2024 | Journal article | 4 |
| Compounded GLP-1 receptor agonists: safety advisory | Australian Therapeutic Goods Administration | TGA Safety Advisory | 2024 | Regulatory document | 0 |
| Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the… | Aronne LJ | JAMA | 2024 | Journal article | 11 |
| Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical… | Camilleri M | American Journal of Gastroenterology | 2024 | Journal article | 0 |
| Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes | Perkovic V | New England Journal of Medicine | 2024 | Journal article | 3 |
| Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian… | Mu Y | The Lancet Diabetes & Endocrinology | 2024 | Journal article | 0 |
| FDA’s concerns with unapproved GLP-1 drugs used for weight loss | United States Food and Drug Administration | FDA Drug Safety Communication | 2024 | Regulatory document | 0 |
| General Chapter ⟨1225⟩ Validation of Compendial Procedures | United States Pharmacopeial Convention | United States Pharmacopeia — National… | 2024 | Guideline | 15 |
| General Chapter ⟨71⟩ Sterility Tests | United States Pharmacopeial Convention | United States Pharmacopeia — National… | 2024 | Guideline | 5 |
| General Chapter ⟨788⟩ Particulate Matter in Injections | United States Pharmacopeial Convention | United States Pharmacopeia — National… | 2024 | Guideline | 6 |
| General Chapter ⟨85⟩ Bacterial Endotoxins Test | United States Pharmacopeial Convention | United States Pharmacopeia — National… | 2024 | Guideline | 8 |
| General Chapter ⟨921⟩ Water Determination | United States Pharmacopeial Convention | United States Pharmacopeia — National… | 2024 | Guideline | 1 |
| Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind… | le Roux CW | The Lancet Diabetes & Endocrinology | 2024 | Journal article | 11 |
| ICH Q3C(R9) Impurities: Guideline for Residual Solvents | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | ICH Harmonised Guideline | 2024 | Guideline | 9 |
| Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial | Ryan DH | Nature Medicine | 2024 | Journal article | 2 |
| Medical Product Alert N°2/2024: falsified semaglutide | World Health Organization | WHO Medical Product Alert | 2024 | Regulatory document | 0 |
| Mounjaro (tirzepatide) — Summary of Product Characteristics | European Medicines Agency | EMA European Public Assessment Report | 2024 | Regulatory document | 1 |
| MOUNJARO (tirzepatide) injection, for subcutaneous use — Highlights of Prescribing Information | United States Food and Drug Administration | FDA Approved Labeling | 2024 | Regulatory document | 1 |
| OZEMPIC (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information | United States Food and Drug Administration | FDA Approved Labeling | 2024 | Regulatory document | 0 |
| Quality of peptide products obtained from unregulated online suppliers: an analytical survey | Bhattacharyya S | Journal of Pharmaceutical Sciences | 2024 | Journal article | 24 |
| Semaglutide in patients with obesity-related heart failure and type 2 diabetes | Kosiborod MN | New England Journal of Medicine | 2024 | Journal article | 0 |
| Tirzepatide for the treatment of obstructive sleep apnea and obesity | Malhotra A | New England Journal of Medicine | 2024 | Journal article | 11 |
| Wegovy (semaglutide) — Summary of Product Characteristics | European Medicines Agency | EMA European Public Assessment Report | 2024 | Regulatory document | 1 |
| WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information | United States Food and Drug Administration | FDA Approved Labeling | 2024 | Regulatory document | 3 |
| ZEPBOUND (tirzepatide) injection, for subcutaneous use — Highlights of Prescribing Information | United States Food and Drug Administration | FDA Approved Labeling | 2024 | Regulatory document | 1 |
| Analytical and forensic aspects of counterfeit peptide hormones | Carvalho M | Drug Testing and Analysis | 2023 | Journal article | 4 |
| Daily oral GLP-1 receptor agonist orforglipron for adults with obesity | Wharton S | New England Journal of Medicine | 2023 | Journal article | 7 |
| Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in… | Frías JP | The Lancet | 2023 | Journal article | 9 |
| Efficacy and safety of mazdutide in Chinese participants with overweight or obesity: a randomised… | Ji L | Diabetes, Obesity and Metabolism | 2023 | Journal article | 7 |
| Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised… | Frías JP | The Lancet | 2023 | Journal article | 7 |
| Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic… | Saxena AR | JAMA Network Open | 2023 | Journal article | 1 |
| Falsified Ozempic (semaglutide) pens: patient safety alert | Medicines and Healthcare products Regulatory Agency | MHRA Safety Alert | 2023 | Regulatory document | 1 |
| General Chapter ⟨795⟩ and ⟨797⟩ Pharmaceutical Compounding — Nonsterile and Sterile Preparations | United States Pharmacopeial Convention | United States Pharmacopeia — National… | 2023 | Guideline | 2 |
| General Chapter 2.2.29 Liquid Chromatography | European Directorate for the Quality of Medicines & HealthCare | European Pharmacopoeia | 2023 | Guideline | 3 |
| General Monograph 2034 Substances for Pharmaceutical Use | European Directorate for the Quality of Medicines & HealthCare | European Pharmacopoeia | 2023 | Guideline | 4 |
| GLP-1 receptor agonists and the risk of thyroid cancer | Bezin J | Diabetes Care | 2023 | Journal article | 0 |